Product Due Diligence: How to Meet KYP and Protect Your Clients (and Your Firm)

Introduction

Hook: Imagine recommending a product you thought was safe — only to discover later that a model error or issuer-credit shock made it unsuitable. That’s exactly what product due diligence aims to prevent.

Friendly definition: Product Due Diligence is the firm‑level process of identifying, reviewing, documenting, and approving (or rejecting) a financial product for distribution, including assessment of legal, tax, valuation, liquidity, counterparty, operational, model and reputational risks. Closely linked is KYP (Know‑Your‑Product): the obligation of approved persons and the firm to know a product’s features, risks, costs and limitations sufficiently to make and support recommendations consistent with suitability obligations.

You’ll use this guide to understand who does what, what to document, and how to link product attributes to a client’s KYC profile so your recommendations stand up to regulatory and practical scrutiny.

Core Concepts (Recall)

• Dealers must have written procedures that identify, vet and monitor new or non‑standard products and must identify which products require formal review and a maintained product file.
• Product Due Diligence must evaluate legal, tax, accounting, market, liquidity, counterparty, model, operational and reputational risks and record those assessments.
• Dealers determine and enforce distribution scope (general, limited, restricted) through systems, controls and surveillance; approved persons must follow those limits.
• Approved persons must understand material product features, risks, costs and conflicts, complete required training, and document how a product fits a client’s KYC and suitability profile.
• Documentation at both the firm and advisor levels is primary evidence for compliance; material product changes require re‑review equivalent to a new product assessment.
• Reliance on issuer marketing materials alone is insufficient without independent review, validation or documented escalation.

(Reference: IIROC guidance on best practices for product due diligence and client‑focused reforms.)

Detailed Analysis (Understand)

Product due diligence is a shared responsibility. The dealer sets policy, approves (or rejects) products, defines and enforces distribution scopes (general, limited, restricted), and monitors post‑sale. Approved persons apply KYP at the client level — mapping product attributes to a client’s risk tolerance, objectives and constraints — and must escalate when the product or client circumstances fall outside their competence or dealer limits.

Why this matters:

• Complexity and novelty increase the required level of diligence. A superficially similar product may carry materially different risks and therefore needs fresh review.
• Dealers must be able to evidence their gatekeeping role: written policies, a product file that documents legal/tax/valuation/liquidity/counterparty/model/operational/reputational analysis, and a record of distribution limits are essential.
• Approved persons cannot treat KYP as a checklist. The product file supplies the factual basis for client‑level suitability decisions; you must be able to explain how a product’s characteristics relate to a particular client’s KYC profile and document that rationale.

Practical regulatory tools dealers use include pre‑trade controls, coded distribution limits, training, and ongoing surveillance. Client‑focused reforms emphasize the alignment between product target market and suitability obligations; see the CSA/CIRO materials on Client Focused Reforms for related housekeeping rule changes: https://www.ciro.ca/newsroom/publications/client-focused-reforms-housekeeping-rule-changes

Practical Application

Real-world scenarios you should be ready to manage:

• Routine mutual fund: The dealer may accept a fund prospectus as a starting point, but must confirm distributor suitability, disclosure and any dealer‑imposed limits are appropriate and recorded in the product file.
• New structured product: Convene a cross‑functional review (legal, compliance, risk, operations, tax, trading); document conclusions in the product file; define and code distribution limits; prepare training and sales materials; and implement monitoring. Material changes trigger a re‑review. (Guidance: New Product Due Diligence Regulatory Review: https://www.ciro.ca/newsroom/publications/new-product-due-diligence-regulatory-review-common-deficiencies-and-requirements-written-policies)
• Principal‑protected note for retail: The product committee evaluates the protection mechanism, issuer credit risk, liquidity, fees and disclosure and sets the target market. As the approved person, you must confirm client eligibility and record the suitability rationale.
• Equity‑linked note: You should be able to explain payoff calculation, principal protection conditions, issuer credit risk, expected liquidity, embedded fees and scenarios where the note underperforms plain alternatives.
• Asset‑backed securities (ABS) with model‑dependent valuation: If the firm lacks model validation capability or the intended clients lack sophistication, restrict or decline distribution and require independent valuation checks and enhanced disclosure.

For a practical checklist and regulatory notices on product introductions and supervision consult: https://www.ciro.ca/media/851/download

Key Takeaways

• Product Due Diligence is a firm‑level gatekeeping process; KYP is the advisor’s client‑level obligation.
• Always document: product files, distribution limits, training completion, and point‑of‑sale suitability rationale.
• Material product changes = re‑review. Treat due diligence as ongoing, not one‑and‑done.
• Don’t rely solely on issuer materials—perform independent checks and validate models where required.

Study tip for the CIRE: link product features directly to KYC scenarios during practice questions. Demonstrate both firm‑level controls and the approved person’s documented KYP/suitability rationale to show full compliance with expectations.

Further reading: see IIROC Notice 09‑0086 – “Best practices for product due diligence” and related CIRO guidance: https://www.ciro.ca/media/3300/download?inline=1